FIN 403
Alternative Names: FIN403Latest Information Update: 28 Mar 2020
Price :
$50 *
At a glance
- Originator Finch Therapeutics
- Developer Finch Therapeutics Group
- Class Bacteria; Probiotics
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for clinical-Phase-Unknown development in Clostridium-difficile-infections in USA (PO, Capsule)
- 23 Oct 2017 Crestovo has merged with Finch Therapeutics to form Finch Therapeutics Group
- 10 Mar 2017 FIN 403 is available for licensing as of 23 Feb 2017.